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LTX-315, CAPtivating immunity with necrosis
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The "immunological" recognition of cell death as a non-inflammatory (tolerogenic or null) or an inflammatory (immunogenic) event has a crucial role in tumor progression and the response to antineoplastic therapy. Harnessing the immune system to achieve clinical efficacy is realistic in the context of conventional anticancer agents whose outcome mainly relies on the ability to (re)instate tumor-host interaction, thus translating cell death into an immune response. Several factors work in concert to determine whether cell death is immunogenic or not, including the intrinsic antigenicity of cancer cells, the host immunocompetence, the initiating stress stimulus and the cell death pathways engaged. These discoveries prompted Forveille and colleagues to study the nature of such an ICD based on the notion that apoptotic and necrotic subroutes both are immunogenic. 6 Through morphometric and ultrastructural analyses they showed that the appearance of human U2OS osteosarcoma cells 
